[go: up one dir, main page]

WO2019028012A3 - Methods of using pembrolizumab and trebananib - Google Patents

Methods of using pembrolizumab and trebananib Download PDF

Info

Publication number
WO2019028012A3
WO2019028012A3 PCT/US2018/044584 US2018044584W WO2019028012A3 WO 2019028012 A3 WO2019028012 A3 WO 2019028012A3 US 2018044584 W US2018044584 W US 2018044584W WO 2019028012 A3 WO2019028012 A3 WO 2019028012A3
Authority
WO
WIPO (PCT)
Prior art keywords
trebananib
pembrolizumab
methods
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/044584
Other languages
French (fr)
Other versions
WO2019028012A2 (en
WO2019028012A9 (en
Inventor
Frank Stephen HODI
Osama E. RAHMA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of WO2019028012A2 publication Critical patent/WO2019028012A2/en
Publication of WO2019028012A3 publication Critical patent/WO2019028012A3/en
Publication of WO2019028012A9 publication Critical patent/WO2019028012A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G01N33/57585—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods of treating cancer with pembrolizumab and trebananib.
PCT/US2018/044584 2017-07-31 2018-07-31 Methods of using pembrolizumab and trebananib Ceased WO2019028012A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762539176P 2017-07-31 2017-07-31
US62/539,176 2017-07-31

Publications (3)

Publication Number Publication Date
WO2019028012A2 WO2019028012A2 (en) 2019-02-07
WO2019028012A3 true WO2019028012A3 (en) 2019-02-28
WO2019028012A9 WO2019028012A9 (en) 2019-04-18

Family

ID=63407514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/044584 Ceased WO2019028012A2 (en) 2017-07-31 2018-07-31 Methods of using pembrolizumab and trebananib

Country Status (1)

Country Link
WO (1) WO2019028012A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115300624A (en) * 2022-07-08 2022-11-08 中国医学科学院药用植物研究所 Application of ginsenoside and PD-1 blocker in preparation of head and neck squamous cell carcinoma resisting medicine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057367A1 (en) * 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
WO2016170039A1 (en) * 2015-04-23 2016-10-27 F. Hoffmann-La Roche Ag Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057367A1 (en) * 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
WO2016170039A1 (en) * 2015-04-23 2016-10-27 F. Hoffmann-La Roche Ag Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor, ClinicalTrials.gov Identifier: NCT03239145", CLINICALTRIALS.GOV, 1 February 2018 (2018-02-01), pages 1 - 7, XP055519158, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT03239145> [retrieved on 20181025] *
CLAUDIA MARCHETTI ET AL: "Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386)", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. 94, no. 3, 1 June 2015 (2015-06-01), AMSTERDAM, NL, pages 302 - 310, XP055292959, ISSN: 1040-8428, DOI: 10.1016/j.critrevonc.2015.02.001 *
GRANT SHIMAMOTO ET AL: "Peptibodies: A flexible alternative format to antibodies", MABS, vol. 4, no. 5, 1 September 2012 (2012-09-01), US, pages 586 - 591, XP055484059, ISSN: 1942-0862, DOI: 10.4161/mabs.21024 *
ITALIA GRENGA ET AL: "Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 3, no. 1, 17 November 2015 (2015-11-17), XP055357747, DOI: 10.1186/s40425-015-0096-7 *
JOAQUIM BELLMUNT ET AL: "Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma", THE NEW ENGLAND JOURNAL OF MEDICINE, - NEJM -, vol. 376, no. 11, 16 March 2017 (2017-03-16), US, pages 1015 - 1026, XP055518649, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1613683 *
PATRICK A. OTT ET AL: "Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data", FRONTIERS IN ONCOLOGY, vol. 5, 22 September 2015 (2015-09-22), pages 1 - 7, XP055383215, DOI: 10.3389/fonc.2015.00202 *
XINQI WU ET AL: "Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy", CANCER IMMUNOLOGY RESEARCH, vol. 5, no. 1, 1 January 2017 (2017-01-01), US, pages 17 - 28, XP055462687, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-16-0206 *

Also Published As

Publication number Publication date
WO2019028012A2 (en) 2019-02-07
WO2019028012A9 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
WO2016134335A3 (en) Pvrig polypeptides and methods of treatment
WO2018081648A3 (en) Anti-mic antibidies and methods of use
HK1254843A1 (en) Compositions comprising bacterial strains
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
WO2016144728A3 (en) Anti-lilrb antibodies and their use in detecting and treating cancer
WO2016149710A3 (en) Hiv-1 neutralizing antibodies and uses thereof
WO2015153513A8 (en) Anti-ox40 antibodies and methods of use
WO2015073587A3 (en) Synthetic membrane-receiver complexes
WO2017136450A3 (en) Compounds and methods of treating rna-mediated diseases
WO2015179658A3 (en) Anti-gpc3 antibodies and immunoconjugates
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
EP4361178A3 (en) Acid-alpha glucosidase variants and uses thereof
WO2017075173A3 (en) Anti-factor d antibodies and conjugates
MX2018000715A (en) Methods for treating cancer using apilimod.
WO2018083539A3 (en) Coating compositions and methods of use thereof
EP4218736A3 (en) Compositions comprising 15-hepe
SG11201900459RA (en) Mg53 mutants, methods of making the same, and uses thereof
WO2015179835A3 (en) Mit biomarkers and methods using the same
WO2017096303A3 (en) Cerdulatinib for treating hematological cancers
WO2017120527A3 (en) Therapeutic compositions and methods for treating hepatitis b
WO2016167944A3 (en) Compositions and methods for treating autism
WO2016130581A3 (en) Combination cancer therapy
IL280218A (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
WO2019028012A3 (en) Methods of using pembrolizumab and trebananib
SG11202000724XA (en) Methods and compositions for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18762180

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18762180

Country of ref document: EP

Kind code of ref document: A2